అకౌంట్స్ గమనికలుMahamaya Lifesciences Ltd.

Mar 31, 2026

economic benefits will be required to settle the
obligation and a reliable estimate can be made of
the amount of the obligation. Provisions are not
discounted to their present value and are determined
based on the best estimate required to settle the
obligation at the reporting date. These estimates
are reviewed at each reporting date and adjusted
to reflect the current best estimates. The expense
relating to any provision is presented in the statement
of profit and loss, net of any reimbursement.

p) Contingent Liabilities

A Contingent Liability is a possible obligation that
arises from past events whose existence will be
confirmed by the occurrence or non-occurrence
of one or more uncertain future events beyond the
control of the company or a present obligation that
is not recognized because it is not probable that
an outflow of resources will be required to settle
the obligation. A contingent liability also arises
in extremely rare cases where there is a liability
that cannot be recognized because it cannot be
measured reliably. The Company does not recognize
a contingent liability but discloses its existence in
the financial statements.

q) Cash and Cash Equivalents

Cash and cash equivalents comprise Cash-in-hand,
Current Accounts, Fixed Deposits with banks. Cash
equivalents are short-term balances (with an original
maturity of three months or less from the date
of acquisition), highly liquid investments that are
readily convertible into known amounts of cash and
which are subject to insignificant risk of changes in
value. Other Bank Balances are short-term balance
(with original maturity is more than three months but
less than twelve months)

r) Government Grants and Subsidies

o) Provisions

A provision is recognized when the Company has
a present obligation as a result of past event, it is
probable that an outflow of resources embodying

Government grants and subsidies are recognised
where there is reasonable assurance that the Group
will comply with the conditions attached to them
and that the grant / subsidy will be received. Grants
and subsidies of a revenue nature, including export
incentives such as Duty Drawback and Remission of
Duties and Taxes on Exported Products (RoDTEP),
and interest / investment subsidies, are recognised
in the Statement of Profit and Loss on a systematic
basis over the periods necessary to match them
with the related costs which they are intended
to compensate, and are presented under "Other
Operating Income" or "Other Income", as applicable.
Grants in the nature of promoters'' contribution or
relating to an asset are, where applicable, credited
to a capital reserve or deducted from the carrying
amount of the related asset / treated as deferred
income, as appropriate.

Note:

1) Terms/Rights attached to Equity Shares: The company has only one class of Equity Shares having a par value of '' 10/-
per share. Each holder of Equity share is entitled to one vote per share. In the event of liquidation of the Company, the
holders of equity share will be entitled to receive remaining Assets of the Company, after distribution of all preferential
amounts. The distribution will be in proportion to the number of equity shares held by the Share holders.

2) The Equity Shares are not repayable except in the case of a buy back, reduction of capital or winding up in terms of the
provisions of the Companies Act, 2013.

3) Every member of the company holding Equity Shares has a right to attend the General Meeting of the Company and has
a right to speak and on a show of hands, has one vote if he is present in person and on a poll shall have the right to vote
in proportion to his share of the paid-up capital of the company.

4) During the year, the Company completed its Initial Public Offering (IPO) and issued 56,38,800 equity shares of face value
''10 each at an issue price of ''114 per equity share, comprising a premium of ''104 per equity share. The issue resulted in
an increase in the paid-up equity share capital by ''563.8 lakhs and securities premium by ''5864.35 lakhs.

* Bank cash credit limits are secured by hypothecation of stock, book debts and Company property, together with the
personal guarantee of the directors. The facilities carry interest at the rate of 8.65% p.a. with CITI Bank, 10.00% p.a. with
IndusInd Bank and 8.00% p.a. with DBS Bank India Limited, and are repayable on demand.

** Tata Capital Financial Services Limited - WCDL loan sanctioned for a period of 90 days on a rotational basis, carrying
interest at an annualised rate of 11.70% p.a.

*** Equentia Financials - facility availed for a period of 90 days on a rotational basis against purchase bill discounting, carrying
interest at an annualised rate of 14.50% p.a.

**** Yes Bank - WCDL loan sanctioned for a period of 180 days on a rotational basis, carrying interest at an annualised rate of
8.00% p.a.

The Company was listed on the BSE SME Platform on 18 November 2025. In connection with the Initial Public Offering (IPO) and
pursuant to the requirements of the Securities and Exchange Board of India (SEBI) ICDR Regulations, the financial statements
for the financial years 2021-22, 2022-23, 2023-24 and 2024-25 were restated. Accordingly, the impact of such restatements
has been incorporated in these financial statements by way of prior period adjustments in the Statement of Profit and Loss
and corresponding adjustments to the relevant assets and liabilities in the Balance Sheet, wherever applicable, so as to align
the books of account with the restated financial information.

Note 2: The Corporate Social Responsibility (CSR) activities of the Company shall, inter alia, include promotion of organic
farming through the use of biocontrol agents and sustainable management of major diseases affecting mustard and paddy
crops using Trichoderma asperellum under hot and humid conditions.The Company shall also undertake CSR initiatives in the
areas of education and healthcare, including support towards educational infrastructure.

Reasons for variance (where movement exceeds 25%)

Note 1: Reason for variance in Return on Equity Ratio is the substantial increase in equity base during the year pursuant to the
Initial Public Offer, with fresh issue of equity and securities premium aggregating Rs.6,428.23 lakhs (net of issue expenses),
which outpaced the 30.42% growth in profits after tax.

Note 2: Reason for variance in Inventory turnover ratio is the higher inventory build-up at year end (Rs.14,105.26 lakhs as
against Rs.10,020.76 lakhs in the previous year, a growth of 40.76%) to support the scaled-up operations and maintain
adequate stocks in line with the company''s growth plans post listing.

Note 3: Reason for variance in Trade Receivables turnover ratio is the higher receivables outstanding at year end (Rs.7,075.99
lakhs as against Rs.4,846.29 lakhs, a growth of 46.01%) on account of expansion in customer base and increased credit sales,
the growth in receivables being higher than the 24.50% growth in revenue from operations.

Note 4: Reason for variance in Trade Payables turnover ratio is the higher procurement levels to support the increased scale
of operations and improved credit terms negotiated with suppliers, with average trade payables rising to Rs.5,975.47 lakhs
from Rs.3,886.30 lakhs in the previous year.

Note 5: Reason for variance in Debt-Equity Ratio is the significant strengthening of the equity base during the year pursuant
to the Initial Public Offer, with shareholders'' funds increasing from Rs.4,986.71 lakhs to Rs.12,262.79 lakhs (a growth of
145.91%), which has outpaced the proportionate increase in total debt.

Note 6: Reason for variance in Net capital turnover ratio is the sharp increase in average working capital from Rs.1,758.40
lakhs to Rs.5,473.13 lakhs, primarily driven by the substantial build-up in inventories and trade receivables to support the
expanded scale of operations.

Note 7:Reason for variance in Return on Capital Employed is the substantial increase in capital employed from Rs.5,717.24
lakhs to Rs.12,784.43 lakhs (a growth of 123.61%), driven by IPO infusion and additional borrowings to fund expanded
operations, while earnings before interest and tax grew by 33.81%.

33. Leases

The company is having office on operating lease at Gurgaon, Haryana with lock in period of 4 years. The company is also
having godown facilities on rent at multiple locations.

Lease payment charged during the period to the statement of profit and loss amounts to Rs. 24.71 lacs (March 31, 2025: Rs.
10.56 lacs)

34. The government of India has promulgated an Act namely the Micro, and Small Enterprises as per MSMED Act, 2006 which
comes into force with effect from October 2, 2006. As per the Act, the Company is required to identify the Micro, Small
and Medium suppliers and pay them interest on overdue beyond the specified period irrespective of the terms agreed with
suppliers.

35. Details of Dues to micro and small enterprises as defined under MSMED Act, 2006:

The detailed information is given under Note -9 Trade Payables.

39. Segment Reporting

The Company has evaluated the applicability of segment reporting and has concluded that the Company has only one
Primary Business Segment i.e., Agrochemicals and One Geographical reportable segment i.e. Operations mainly within India.
Therefore, Accounting Standard (AS) 17 Segment Reporting is not applicable for the year ended 31st March 2026.

40. IPO Disclosure

The Company was listed on the BSE SME Stock Exchange on 18 November 2025 pursuant to its Initial Public Offering ("IPO").
In connection with the IPO, the Company issued equity shares having a face value of Rs. 10 each at an issue price of Rs. 114
per equity share, including a premium of Rs. 104 per equity share. The public issue comprised an aggregate of 61,78,800
equity shares, consisting of a Fresh Issue of 56,38,800 equity shares by the Company (Rs. 64,28,23,200) and an Offer for Sale
("OFS") of 5,40,000 equity shares by the Promoters. The IPO was undertaken in accordance with the applicable provisions
of the Companies Act, 2013 and the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements)
Regulations, 2018, as amended.

41. Previous year''s figures have been regrouped where necessary to confirm to this year''s classification.

Mar 31, 2025

o) Provisions

A provision is recognized when the Company has a present obligation as a result of past event, it is
probable that an outflow of resources embodying economic benefits will be required to settle the obligation
and a reliable estimate can be made of the amount of the obligation. Provisions are not discounted to their
present value and are determined based on the best estimate required to settle the obligation at the reporting
date. These estimates are reviewed at each reporting date and adjusted to reflect the current best estimates.
The expense relating to any provision is presented in the statement of profit and loss, net of any
reimbursement.

p) Contingent Liabilities

A Contingent Liability is a possible obligation that arises from past events whose existence will be
confirmed by the occurrence or non-occurrence of one or more uncertain future events beyond the control
of the company or a present obligation that is not recognized because it is not probable that an outflow of
resources will be required to settle the obligation. A contingent liability also arises in extremely rare cases
where there is a liability that cannot be recognized because it cannot be measured reliably. The Company
does not recognize a contingent liability but discloses its existence in the financial statements.

q) Cash and Cash Equivalents

Cash and cash equivalents comprises Cash-in-hand, Current Accounts, Fixed Deposits with banks.
Cash equivalents are short-term balances (with an original maturity of three months or less from the
date of acquisition), highly liquid investments that are readily convertible into known amounts of
cash and which are subject to insignificant risk of changes in value. Other Bank Balances are
short-term balance (with original maturity is more than three months but less than twelve months).

32. Related Party Transactions

The Company has identified the following persons as Related Parties and the nature of relationship
with them is as follows:

Name of Related Parties and Relationship:

Key Management Personnel

- Mr. Krishnamurthy Ganesan - Managing Director

- Mrs. Lalitha Krishnamurthy - Whole-time Director

- Mr. Prashant Krishnamurthy - Executive Director & Chief Financial Officer (CFO)

Wholly Owned Subsidiary Companies

- Mahamaya Lifesciences FZE (incorporated on 5th April,2017)

(See Note no: 12 - Non-Current Investments for details)

Entities over which Key Management Personnel have significant influence

- Chemlinks India

- Clearship Travels & Tours Pvt Ltd

33. Leases

The company is having office on operating lease at Gurgaon, Haryana with lock in period of 2 years. The
company is also having godown facilities on rent at multiple locations.

Lease payment charged during the period to the statement of profit and loss amounts to Rs. 10.56 lacs
(March 31, 2024: Rs.10.64 lacs)

There are no Future lease payments payable under above lease during non-cancellable period

34. The government of India has promulgated an Act namely the Micro, and Small Enterprises as per
MSMED Act, 2006 which comes into force with effect from October 2, 2006. As per the Act, the
Company is required to identify the Micro, Small and Medium suppliers and pay them interest on
overdue beyond the specified period irrespective of the terms agreed with suppliers.

39. Segment Reporting

The Company has evaluated the applicability of segment reporting and has concluded that the Company
has only one Primary Business Segment i.e., Agrochemicals and One Geographical reportable segment
i.e. Operations mainly within India. The overall performance is reviewed by the Board of Directors.
Thus, the segment revenue, expenses, results, assets and liabilities are same as reflected in the financial
statements as at and for the year ended 31st March 2025.

40. The Company has filed DRHP in the BSE SME PLATFORM ON 27TH FEBRUARY 2025, for the
purpose of Initial Public Offering and the application is under process. As part of the DRHP filing, the
Financial Statements were restated for the last 3 years (21-22, 22-23 & 23-24) to match with the SEBI
ICDR regulations. The changes made to the last 3 years'' financials have been given effect in the books of
accounts in these financials as prior period adjustments in the Profit and Loss account and in the Balance
Sheet against the relevant Asset/ Liability to reflect the restated figures.

41. Previous year''s figures have been regrouped where necessary to confirm to this year''s classification.
As per our report of even date

For N Naresh & Co For and on behalf of board of directors of

Chartered Accountants Mahamaya Lifesciences Limited

Firm Registration no: 011293S

Sd/- Sd/- Sd/-

CA Kumar E Krishnamurthy Lalitha

Partner Ganesan Krishnamurthy

Membership No. : 217549 Managing Whole-time

Director Director

DIN:00270539 DIN: 00425675

Place : New Delhi Sd/- Sd/-

Date : 14-06-2025

Prashant Shilpi Bhardwaj

Krishnamurthy Company Secretary

Chief Financial Membership No. : A24444

Officer

Disclaimer: This is 3rd Party content/feed, viewers are requested to use their discretion and conduct proper diligence before investing, GoodReturns does not take any liability on the genuineness and correctness of the information in this article

Notifications
Settings
Clear Notifications
Notifications
Use the toggle to switch on notifications
  • Block for 8 hours
  • Block for 12 hours
  • Block for 24 hours
  • Don't block
Gender
Select your Gender
  • Male
  • Female
  • Others
Age
Select your Age Range
  • Under 18
  • 18 to 25
  • 26 to 35
  • 36 to 45
  • 45 to 55
  • 55+